Orvepitant for chronic cough therapy
US9750739B2 · kind B2 · utility
1Cited by
0References
11Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Dec 27, 2016 |
| Grant date | Sep 5, 2017 |
| Priority date | — |
| Expiry date | Dec 27, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to the new use of the compound 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide (orvepitant) or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing it for the treatment of chronic cough, including chronic refractory cough and to combinations for such a use.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.